Trastuzumab Single-Drug Therapy after Failure of Cytotoxic Treatment for Metastatic Breast Cancer

Publisher： Karger

E-ISSN： 2296-5262|33|8-9|425-430

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.33, Iss.8-9, 2010-07, pp. : 425-430

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Trastuzumab as Single Agent Therapy for HER2-Positive Metastatic Breast Cancer

By  

Oncology Research and Treatment, Vol. 33, Iss. 8-9, 2010-07 ,pp. : 420-421

Karger

Access to resources Recommend Favorite

Effectiveness of Trastuzumab (HerceptinTM) in a Patient with Locally Recurrent Breast Cancer after Cardiac Failure Caused by Severe Cytotoxic Pretreatment

By  

Oncology, Vol. 61, Iss. 4, 2001-11 ,pp. : 271-274

Karger

Access to resources Recommend Favorite

Cardiotoxicity Related to Long‐Term Trastuzumab Therapy in Metastatic Breast Cancer: The Potential Role of Treatment Duration and Cardiac Risk Factors

By  

THE BREAST JOURNAL, Vol. 21, Iss. 3, 2015-05 ,pp. : 318-321

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phase II Study of Single-Agent Pegylated Liposomal Doxorubicin HCl (PLD) in Metastatic Breast Cancer After First-Line Treatment Failure

By  

Oncology Research and Treatment, Vol. 27, Iss. 5, 2004-10 ,pp. : 441-446

Karger

Access to resources Recommend Favorite

Management of Patients with Brain Metastases Receiving Trastuzumab Treatment for Metastatic Breast Cancer

By  

Oncology Research and Treatment, Vol. 34, Iss. 6, 2011-05 ,pp. : 304-308

Karger

Access to resources Recommend Favorite